Post-marketing experiences with belimumab in the treatment of SLE patients.

Abstract

Belimumab (Benlysta) is a human recombinant monoclonal antibody that targets and inhibits soluble B-lymphocyte stimulator, also known as B-cell activating factor, a proliferation and survival factor for B cells. The published clinical trials data showed that in patients with active systemic lupus erythematosus (SLE), belimumab effectively reduced peripheral B-cell levels and improved disease activity. This article reviews the belimumab clinical trials and the post-marketing experience with belimumab in the treatment of those lupus patients with persistent active disease despite current standard of care (SOC) therapy.

• Authors: Anca D Askanase, Jinoos Yazdany, Charles T Molta
• Journal: Rheumatic diseases clinics of North America (Rheum Dis Clin North Am) Vol. 40 Issue 3 Pg. 507-17, viii (Aug 2014) ISSN: 1558-3163 [Electronic] United States
• PMID: 25034159 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Humanized
• B-Cell Activating Factor
• Immunosuppressive Agents
• belimumab

Topics

• Adult
• Antibodies, Monoclonal, Humanized (therapeutic use)
• B-Cell Activating Factor (immunology)
• Female
• Humans
• Immunosuppressive Agents (therapeutic use)
• Lupus Erythematosus, Systemic (drug therapy, immunology)
• Male
• Observational Studies as Topic
• Product Surveillance, Postmarketing (methods)
• Randomized Controlled Trials as Topic
• Treatment Outcome